Scleroatrophic lichen in women: improvement of methods for an objective assessment of clinical manifestations and therapy


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. The prevalence of scleroatrophic lichen and the lack of unified approaches to the diagnosis and treatment of this disease require the development of new approaches to both diagnosis and improvement of treatment methods for this nosology. Objective. Offering the methods for an objective assessment of the effectiveness of the treatment of vulvar lichen sclerosus (VLS) and evaluation of the stage-by-stage treatment of disease using these methods. The LS-S index was proposed for assessing the area of skin lesion, and LS-A index - for evaluating the activity of the skin process in VLS. The LS-S index was based on the assessment of the lesion area by subdivision of the vulva into zones, while the LS-A index includes the main clinical manifestations of VLS and their severity. The practical application of the indices against the background of a three-stage treatment of VLS was evaluated. Methods. The observation group consisted of 41 patients with vulvar lichen sclerosus aged 19 to 59 years. Using the LS-S index, the patients were classified as follows: 27 women had a lesion estimated at 9 points (there were no perianal lesions in this group); 11 patients had a lesion area of 5 points, and 3 patients - 7points An assessment was performed using the developed indices of vulvar lichen sclerosus, allowing to evaluate the activity of the skin process and its area. Evaluation was carried out before treatment, on the 14th, 30th, 90th and 120th days. The stages of treatment consisted in the sequential use of topical glucocorticosteroids, injections of autologous plasma, and fractional CO2 laser. Results. The use of indices for assessing the area and activity of the skin process after the stage-by-stage treatment showed the convenience and simplicity of their use and made it possible to objectify the data obtained as a result of treatment: after the three-stage treatment, 27 women had a lesion estimated at 5 points (there were no perianal lesions in this group); 11 patients had a lesion area of 2 points, and 3 patients had a lesion area of 4 points, which corresponded to a distinct positive dynamics, having a numerical expression. Administred therapy was not accompanied by significant adverse events. Conclusion. The use of the index of activity of the skin process and the index for assessing the area of skin lesion of the vulva region in VLS is a convenient and practical tool for an objective assessment of the dynamics of skin changes during therapy, which includes a three-stage approach with sequential use of topical corticosteroids, injections of autologous plasma, and fractional CO2 laser.

Full Text

Restricted Access

About the authors

A. V Ignatovsky

St. Petersburg State University, Department of Infectious Diseases, Epidemiology and Dermatovenerology

Email: derm@list.ru

References

  1. Brenninkmeijer E., Schram M., Leeflang M., et al. Diagnostic criteria for atopic dermatitis: a systematic review. Br J Dermatol. 2008;158(4):754-65. doi: 10.1111/j.1365-2133.2007.08412.x
  2. Gottlieb A.B., Chaudhari U., Baker D.G., et al. The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area Severity Index (PAS!) and Physician's Global Assessment (PGA): a comparison. J Drugs Dermatol. 2003;2:260-66.
  3. Кубанов А.А., Карамова А.Э., Знаменская Л.Ф. и др. Индекс PAS! (Psoriasis Area and Severity Index) в оценке клинических проявлений псориаза PASI. Вестник дерматологии и венерологии. 2016;(4):33-38. Doi: https://doi. org/10.25208/0042-4609-2016-0-4-36-40
  4. Jacobson C.C., Kimball A.B. Rethinking the Psoriasis Area and Severity Index: the impact of area should be increased. Br J Dermatol 2004;151(2): 38187. doi: 10.1111/j.1365-2133.2004.06035.x.
  5. Mattei P.L., Corey K.C., Kimball A.B. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol 2014;28(3):333-37.
  6. Langley R., et al. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol. 2004;51(4):563 - 69. Doi: 10.1016/j. jaad.2004.04.012.
  7. Федотова К.Ю. Применение импульсного поляризованного света и топического ингибитора кальциневрина у больных красным плоским лишаем. Автореф. дисс. канд. мед. наук. М., 2016. 137 с
  8. Medsger T.A. Jr, Silman A.J., Steen V.D., et al. A disease severity scale for systemic sclerosis: development and testing. J Rheum. 1999;26(10):2159-67.
  9. Medsger T.A. Jr. Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic wellbeing. Rheum Dis Clin North Am. 2003;29(2):255-73. doi: 10.1016/S0889-857X(03)00023-1.
  10. Minier T., Nagy Z., Balint Z., еt al. Constract validity evaluation of the European Scleroderma Study Group activity Index and investigation of possible new disease activity markers in systemic sclerosis. Rheumatology. 2010;49:1133-31. doi: 10.1093/rheumatology/keq022.
  11. Della Rossa A., Valentini G., Bombardieri S., et al. European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients of 19 centres. Ann Rheum Dis. 2001;60:585-91. doi: 10.1136/ard.60.6.585.
  12. Valentini G., Bencivelli W., Bombardieri S., et al. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of preliminary activity criteria. Ann Rheum Dis. 2003;62:901-3. doi: 10.1136/ard.62.9.901.
  13. Arkachaisri T, Pino S. Localized scleroderma severity index and global assessments: a pilot study of outcome instruments. J Rheumatol. 2008;35:650-57.
  14. Marsol I. Update on the classification and treatment of localized scleroderma. Actas Dermo-Sifiliograficas (English edition). 2013;104(8): 654-66.
  15. Kreuter A., Krieg T., Worm M., et al. German guidelines for the diagnosis and therapy of localized scleroderma; J Dtsch Dermatol Ges. 2016;14(2):199-216. Doi: 10.1111/ ddg.12724.
  16. Ахмеров Р.Р. Регенеративная медицина на основе аутологичной плазмы. Технология PlasmoliftingTM. М.: Литтерра, 2014. С. 144.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2019 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies